The University of Calgary Faculty of Medicine was established in 1967 and renamed the Cumming School of Medicine in 2014. It is one of two medical schools in Alberta and one of 17 in Canada.

During the past decade, University of Calgary, Cumming School of Medicine conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 4 clinical trials were completed, i.e. on average, 30.8% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 2 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Calgary, Cumming School of Medicine" #1 sponsor was "University of Calgary" with 8 trials, followed by "Amgen" with 2 trials sponsored, "CymaBay Therapeutics, Inc." with 2 trials sponsored, "Celgene" with 1 trials sponsored and "Ferring Pharmaceuticals" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Calgary, Cumming School of Medicine" #1 collaborator was "Canadian Institutes of Health Research (CIHR)" with 2 trials as a collaborator, "Alberta Innovation and Science" with 1 trials as a collaborator, "Alzheimer's Association" with 1 trials as a collaborator, "Canadian Foundation for Dietetic Research (CFDR)" with 1 trials as a collaborator and "Cumming school of medicine" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "University of Calgary, Cumming School of Medicine" are "Proof of Concept" (2 trials), "Active Ulcerative Colitis" (1 trials), "Alzheimer Disease" (1 trials), "Bipolar Disorder" (1 trials) and "Complication of Prematurity" (1 trials). Many other conditions were trialed in "University of Calgary, Cumming School of Medicine" in a lesser frequency.

Most popular intervention types in "University of Calgary, Cumming School of Medicine" are "Drug" (12 trials), "Device" (3 trials), "Other" (2 trials), "Biological" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "5-ASA (5-Aminosalicylate)" (1 trials), "Anodal Transcranial direct-current stimulation" (1 trials), "Apremilast" (1 trials) and "Atorvastatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Calgary, Cumming School of Medicine" are 17 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "University of Calgary, Cumming School of Medicine". 1 are not yet recruiting, 5 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in University of Calgary, Cumming School of Medicine, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in University of Calgary, Cumming School of Medicine, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 4 trials that are defined as “Not Applicable".